The Drug Delivery to the Lungs (DDL) meeting was due to return to the Edinburgh International Conference Centre December 9-11 this year following the celebration of its 30th anniversary and it's 15th year bringing hundreds of OINDP experts to Edinburgh, UK in 2019; but due to the COVID-19 epidemic, it will be at least 2021 before the meeting returns to Scotland. A … [Read more...] about DDL 2020 to offer virtual meeting for free
News
Revelation Biosciences initiates Phase 1 trial of REVTx-99 intranasal PHAD
Revelation Biosciences, which announced in October 2020 that the TGA had approved plans for a Phase 1 study of its REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), said that it has now initiated the trial. According to the company, 8 healthy volunteers have already received either REVTx-99 or placebo in the single ascending dose study, which is … [Read more...] about Revelation Biosciences initiates Phase 1 trial of REVTx-99 intranasal PHAD
Kindeva Drug Delivery begins construction of new headquarters
CDMO Kindeva Drug Delivery announced that it has broken ground on a new 137,500 sq ft headquarters building in Woodbury, MN, USA; the company anticipates that the building will be opened in the latter half of 2021. Kindeva, formerly 3M Drug Delivery Systems, offers a wide range of services to support OINDP development and manufacturing, ranging from formulation to … [Read more...] about Kindeva Drug Delivery begins construction of new headquarters
BlueWillow and Medigen partner on development of intranasal vaccine to prevent COVID-19
Medigen Vaccine Biologics and BlueWillow Biologics have partnered for development of S-2P-NE-01, an intranasal vaccine against the SARS-CoV-2 virus, the companies said. According to the announcement, the vaccine will include BlueWillow's NanoVax nasal vaccine adjuvant and Medigen's S-2P spike protein; preclinical studies in mice have shown that the combination … [Read more...] about BlueWillow and Medigen partner on development of intranasal vaccine to prevent COVID-19
TFF and Felix Biotechnology sign letter of intent for proposed development of inhaled bacteriophage for the treatment of lung infections
TFF Pharmaceuticals and Felix Biotechnology have signed a non-binding letter of intent for a proposed agreement regarding development of an inhaled dry powder bacteriophage for the treatment of lung infections. Felix would need to successfully complete a Series A financing before entering into a definitive agreement, which would provide for Felix to make an upfront … [Read more...] about TFF and Felix Biotechnology sign letter of intent for proposed development of inhaled bacteriophage for the treatment of lung infections
Altimmune signs deal with Lonza for AdCOVID manufacturing
Altimmune has signed a manufacturing agreement with Lonza for its AdCOVID intranasal vaccine candidate for the prevention of COVID-19, the companies said. In March 2020, Altimmune announced that it had partnered with the University of Alabama Birmingham for development of AdCOVID; the company subsequently announced an agreement with DynPort Vaccine Company for funding … [Read more...] about Altimmune signs deal with Lonza for AdCOVID manufacturing
Impel Neuropharma submits NDA for its intranasal DHE for the treatment of migraine
Impel NeuroPharma announced that it has submitted an NDA for its INP104 dihydroergotamine mesylate intranasal (DHE) for the treatment of migraine headaches with or without aura, which is delivered via the company's Precision Olfactory Delivery (POD) technology. Impel reported positive results from the STOP 301 Phase 3 trial of INP104 in June 2020. Impel … [Read more...] about Impel Neuropharma submits NDA for its intranasal DHE for the treatment of migraine
Aptar acquires Cohero Health
Aptar has announced its acquisition of Cohero Health and all of its assets, including Cohero's HeroTracker inhaler sensors, BreatheSmart app and platform, and mSpirometer sensors. Cohero Health CEO Joe Condurso will join Aptar Pharma. Since mid-2019, Aptar has acquired a number of OINDP companies, including connected device company Sonmol, training device maker Noble … [Read more...] about Aptar acquires Cohero Health
FDA approves Bronchitol mannitol DPI
The FDA has approved Chiesi's Bronchitol mannitol DPI for the treatment of cystic fibrosis in adult CF patients after a lengthy review process. The FDA issued a complete response letter to the original NDA in 2013, and Chiesi re-submitted the application in December 2018. The FDA’s Pulmonary‐Allergy Drugs Advisory Committee (PADAC) voted to recommend approval of the … [Read more...] about FDA approves Bronchitol mannitol DPI
TFF and Augmenta Bioworks partner on inhaled mAbs for COVID-19
TFF Pharmaceuticals and Augmenta Bioworks have announced a an agreement to collaborate on development of inhaled dry powder monoclonal antibodies (mAbs) for the treatment of COVID-19 based on Augmenta’s mAbs and TFF's thin film freezing particle technology. TFF will also have an option on two more Augmenta mAbs, which it could develop for the treatment of other … [Read more...] about TFF and Augmenta Bioworks partner on inhaled mAbs for COVID-19